NCT00000696View on ClinicalTrials.gov

A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

November 30, 1993

Conditions

HIV Infections

Interventions

DRUG

Interferon alfa-2a

DRUG

Zidovudine

Trial Locations (6)

10029

Beth Israel Med. Ctr. (Mt. Sinai), New York

55455

University of Minnesota, ACTU, Minneapolis

90033

USC CRS, Los Angeles

Unknown

Univ. of Miami AIDS CRS, Miami

Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU, New Orleans

Massachusetts General Hospital ACTG CRS, Boston

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000696 - A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease | Biotech Hunter | Biotech Hunter